Aryldiazoquinoline based multifunctional small molecules for modulating Aβ₄₂ aggregation and cholinesterase activity related to Alzheimer's disease.

ABSTRACT: Research continues to find a breakthrough for the treatment of Alzheimer's Disease (AD) due to its complicated pathology. Presented herein is a novel series of arydiazoquinoline molecules investigated for their multifunctional properties against the factors contributing to Alzheimer's disease (AD). The inhibitory properties of fourteen closely related aryldiazoquinoline derivatives have been evaluated for their inhibitory effect on Aβ₄₂ peptide aggregation. Most of these molecules inhibited Aβ₄₂ fibrillation by 50-80%. Selected molecules were also investigated for their binding behaviour to preformed Aβ₄₀ aggregates indicating a nanomolar affinity. In addition, these compounds were further investigated as cholinesterase inhibitors. Interestingly, some of th

SUBMITTER: Rana M 

PROVIDER: S-EPMC9055851 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature